Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren’s syndrome?

R Manthorpe, C Benoni, L Jacobsson, Z Kirtava, Å Larsson, R Liedholm, C Nyhagen, H Tabery, E Theander

Abstract

Objectives—Prospectively collected computer database information was previously assessed on a cohort of 300 patients who fulfilled the Copenhagen classification criteria for primary Sjögren’s syndrome. Analysis of the clinical data showed that patients who smoked had a decreased lower lip salivary gland focus score (p<0.05). The aim of this original report is to describe the tobacco habits in patients with primary Sjögren’s syndrome or stomatitis sicca only and to determine if there is a correlation between smoking habits and focus score in lower lip biopsies as well as circulating autoantibodies and IgG.

Methods—All living patients with primary Sjögren’s syndrome or stomatitis sicca only, who were still in contact with the Sjögren’s Syndrome Research Centre were asked to fill in a detailed questionnaire concerning present and past smoking habits, which was compared with smoking habits in a sex and age matched population. In addition, the patients previous lower lip biopsies were blindly re-evaluated and divided by the presence of focus score (focus score = number of lymphocyte foci per 4 mm² glandular tissue) into those being normal (focus score ≤ 1) or abnormal (focus score > 1). Furthermore the cohort was divided into three groups; 10–45, 46–60 and > 61 years of age. Finally the focus score was related to the smoking habits. Seroimmunological (ANA; anti-SSA/Ro antibodies; anti-SSB/La antibodies; IgM-RF and IgG) samples were analysed routinely.

Results—The questionnaire was answered by 98% (n=355) of the cohort and the percentage of current smokers, former smokers and historical non-smokers at the time of lower lip biopsy was not statistically different from that of the control group. Cigarette smoking at the time of lower lip biopsy is associated with lower risk of abnormal focus score (p<0.001; odds ratio 0.29, 95%CI 0.16 to 0.50). The odds ratio for having focal sialadenitis (focus score > 1) compared with having a non-focal sialadenitis or normal biopsy (focus score ≤ 1) was decreased in all three age groups (10–45: odds ratio 0.27, 95%CI 0.11 to 0.71; 46–60: odds ratio 0.22, 95%CI 0.08 to 0.59; and > 61: odds ratio 0.36, 95%CI 0.10 to 1.43) although there was only statistical significance in the two younger age groups. Moreover, among current smokers at the time of the lower lip biopsy there was a decreasing odds ratio for an abnormal lip focus score with increasing number of cigarettes smoked per week (p trend 0.00). In the group of former smokers, which included patients that had stopped smoking up to 30 years ago, the results were in between those of the smokers and the historical non-smokers (odds ratio 0.57, 95%CI 0.34 to 0.97, compared with never smokers). Present or past smoking did not correlate with the function of the salivary glands as judged by unstimulated whole sialometry, stimulated whole sialometry or salivary gland scintigraphy. Among former smokers, the median time lapse between the first symptom of primary Sjögren’s syndrome and the performance of the lower lip biopsy was approximately half as long as the median time lapse between smoking cessation and biopsy (8 versus 15 years). Hence, symptoms of Sjögren’s syndrome are unlikely to have had a significant influence on smoking habits at the time of the biopsy. Among the seroimmunological results only anti-SSA/Ro and anti-SSB/La antibodies reached statistical significance in a manner similar to the way smoking influenced the focus score in lower lip biopsies. On the other hand the level of significance was consistently more
pronounced for the influence of smoking on the focus score than for the influence on anti-SSA/Ro and anti-SSB/La autoantibodies.

Conclusion—This is believed to be the first report showing that cigarette smoking is negatively associated with focal sialadenitis—focus score >1—in lower lip biopsy in patients with primary Sjögren’s syndrome. Furthermore, tobacco seems to decrease the focus score in a dose dependent manner. Smoking may also negatively influence the presence of anti-SSA/Ro and/or anti-SSB/La antibodies in circulating blood. Thus, smoking habits of patients might invalidate the use of both lower lip salivary gland focus score and of anti-SSA/anti-SSB antibodies. It is suggested that the simultaneous performance of other objective tests is required to avoid misdiagnosis of oral involvement in smoking and former smoking patients. Therefore, classification criteria for Sjögren’s syndrome that more or less rely on an abnormal focus score and/or presence of anti-SSA/anti-SSB antibodies should be used with great caution.

Methods

PATIENTS AND DEFINITIONS

Since late 1984 we have prospectively computerised symptoms, signs, haematological, serological and immunological data from patients fulfilling the Copenhagen classification criteria for primary SS. Diagnosis was based on at least two abnormal objective tests for the lacrimal glands (keratoconjunctivitis sicca) and at least two abnormal objective test for the salivary glands (stomatitis sicca). In patients with normal lower lip focus score (<1) and at least two objective oral tests should be abnormal before the requirement for stomatitis sicca is fulfilled—most often unstimulated whole sialometry (abnormal if ≤ 1.5 ml/15 min) and salivary gland scintigraphy, but a few times sialography was used.

As our prospective data did not contain a detailed tobacco history, we mailed a questionnaire (see below) to those patients still being seen at our SS Research Centre. New patients were asked to fill in the smoking questionnaire as well.

SMOKING QUESTIONNAIRE

The formula had the following questions:

(1) Are you a current smoker? If yes, (a) Do you smoke regularly? or (b) irregularly? Note: As many patients consider themselves as only feast smokers, both subgroups should state the year they started and the number of cigarettes (or packages) smoked per week.

(2) Are you a former smoker? If yes, (a) What year did you start? (b) What year did you stop? (c) How many cigarettes (or packages) did you smoke on average per week? (d) Did you use nicotine chewing gum and/or patches to reduce stopping? (e) Are you still using nicotine chewing gum and/or patches? If yes, In what amounts?

(3) Have you ever smoked?

(4) Do you take snuff? If yes, How many grams are you using per week?

For questions 1 and 2, the patients had the option to report pipe, cigars and/or cheroots instead of cigarettes.
Patients were asked to return their answer in a prepaid stamped envelope. If no answer was received after two months, the patients received a telephone call or a second reminder letter.

CONTROLS
During 1993–94, 2000 randomly selected women and 2000 randomly selected men living in Malmö (250 000 inhabitants) and born 1913, 1923, 1933, 1943, 1953, 1963, 1968 and 1973 participated in a health study. Between 75% and 80% reported about their smoking habits and these were divided into three groups: historical non-smokers (= never smokers and feast smokers), former smokers and current smokers.

As 90% of patients with primary SS and stomatitis sicca only are women we composed a sex matched control group with a 9:1 female: male ratio for each 10 year period within the total 21–81 years of age to evaluate smoking habits in normal controls. The few patients with primary SS who were younger than 21 or older than 81 years of age were, for statistical purposes, considered to be 21 or 81 years of age, respectively.

FOCAL SIALADENITIS IN LOWER LIP BIOPSIES
To determine an accurate focus score, the previous lower lip biopsies were blindly re-evaluated by our specialist in oral pathology (ÅL). A full description was performed and focal sialadenitis was expressed as lymphocytic foci per defined area of each salivary tissue specimen. Thereupon, the focus score of lymphocytic foci/4 mm² was calculated. A cut off focus score > 1 was defined as abnormal although it occasionally might occur in normal or non-Sjögren’s patients with other diseases.

IMMUNOLOGICAL DATA
Serum/plasma samples for the analyses of the following immunological data were taken at subsequent visits: anti-nuclear antibodies (ANA); anti-SSA (Ro 52 and 60) antibodies; anti-SSB (La 48) antibodies; IgM-RF; IgG. All analyses were performed routinely at the university hospital clinical chemistry or medical microbiology laboratories.

During the first years the ANA analyses were performed by immunofluorescence using rat liver sections as antigen. From 1992 the HEp-2 cells were used as antigen substrate. For women titres ≥ 64; ≥ 128 or ≥ 256 were considered positive in the age groups ≤ 45 years; 46–60 years or ≥ 61 years, respectively. For men one titre lower in the corresponding age group was considered positive.

IgM-RF was analysed by the classic haemagglutination method or by the agglutination method using plastic particles as substrate. Titres ≥ 64 by the haemagglutination method or ≥ 80 by the agglutination method were considered positive.

Anti-SSA (Ro 52 and/or 60) and anti-SSB (La 48) antibodies were analysed by immunodiffusion and results were registered either positive or negative.

For p-IgG values ≥ 14.9 g/l were considered equivalent with hyper-IgG-globulinaemia.

STATISTICS
Statistical calculations were done using the χ² test, Mann-Whitney U non-parametric or Kruskal-Wallis test. p Values <0.05 were considered significant.

Results
MATERIAL SIZE
Our computerised patient material consists of information from 386 patients of whom 35 had stomatitis sicca only. Twenty four of the 386 patients had died or have no further contact with our Research Centre. A total of 362 smoking questionnaires were thus distributed to the patients. At the time of diagnosis 90.5% were women with median age 53.7 years (interquartile range: 42.7–61.7), while the median age for men was 48.3 years (interquartile range: 40.3–58.9).

ANSWERED SMOKING QUESTIONNAIRE
Eighty nine per cent of the patients returned the completed questionnaire without reminders. A further 9% returned it after a reminder or answered a telephone call. The cohort thus comprised 355 patients (98%) with a valid answered smoking questionnaire. When presenting results, the cohort was subdivided into three age groups at the time of diagnosis: 10–45, 46–60 and ≥ 61 years (tables 1 and 2).

---

Table 1: Smoking habits of patients with primary Sjögren’s syndrome or stomatitis sicca only at the time of lower lip biopsy, divided into three different age groups, and compared with control group

<table>
<thead>
<tr>
<th>Year of age at the time of biopsy</th>
<th>10–45</th>
<th>46–60</th>
<th>≥ 61</th>
<th>Total</th>
<th>SS patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never smoked with valid biopsy</td>
<td>42</td>
<td>45</td>
<td>68</td>
<td>155</td>
<td>180 = Historical</td>
<td>51% non-smokers</td>
</tr>
<tr>
<td>Never smoked with non-valid biopsy</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>9</td>
<td>51% non-smokers</td>
<td></td>
</tr>
<tr>
<td>Never smoked and never biopsy</td>
<td>5</td>
<td>5</td>
<td>6</td>
<td>16</td>
<td>50% non-smokers</td>
<td></td>
</tr>
<tr>
<td>Current smokers with valid biopsy</td>
<td>28</td>
<td>25</td>
<td>8</td>
<td>61</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>Current smokers with non-valid biopsy</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2%</td>
<td></td>
</tr>
<tr>
<td>Current smokers and never biopsy</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>24%</td>
<td></td>
</tr>
<tr>
<td>Former smokers who smoked at the time of lip biopsy</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>28%</td>
<td></td>
</tr>
<tr>
<td>Former smokers who stopped before the time of lip biopsy</td>
<td>8</td>
<td>6</td>
<td>4</td>
<td>18</td>
<td>28%</td>
<td></td>
</tr>
<tr>
<td>Total number of patients and controls</td>
<td>107</td>
<td>123</td>
<td>125</td>
<td>355</td>
<td>355</td>
<td></td>
</tr>
</tbody>
</table>

SS patients = primary Sjögren’s syndrome plus stomatitis sicca only patients. Never smoked = historical non-smokers (see text).
Lower frequency of focal lip sialadenitis in smoking patients

FOCUS SCORE IN LOWER LIP BIOPSIES AND THE INFLUENCE OF SMOKING

Table 2 shows that current smokers have a substantially reduced frequency of abnormal focus score in the lower lip biopsy when compared with patients who had never smoked (p<0.001; OR 0.27). In other words, the frequency of non-focal sialadenitis or normal biopsy findings, for example, focus score ≤1 is increased in smokers. When dividing the data into the three age groups, the odds ratio for a positive biopsy was decreased in all age groups (10–45 years: OR = 0.27; 46–60 years: OR = 0.22; ≥61 years: OR = 0.36), although this was only statistically significant in the two younger age groups (table 2).

CURRENT SMOKERS’ CIGARETTE USE AT THE TIME OF LOWER LIP BIOPSY IN RELATION TO FOCAL OR NON-FOCAL SIALADENITIS

Table 3 shows the weekly cigarette consumption among the 79 current smokers with a valid biopsy. The maximum number was 280 cigarettes weekly.

The weekly average cigarette consumption was 64 in those with focal sialadenitis and 88 in those with non-focal sialadenitis. In the group of smokers, the odds ratio for having focal sialadenitis compared with non-focal sialadenitis decreased from 3.5 to 0.1 with increased number of cigarettes smoked per week (p for linear trend = 0.00) (table 3).

For smokers there seems to be a threshold between focal (focus score >1) and non-focal sialadenitis at around 21 cigarettes weekly—the odds ratio being <1 if the cigarette consumption is more than 21 weekly (table 3).

LOWE R LIP BIOPSY OF FORMER SMOKERS IN RELATION TO FOCAL OR NON-FOCAL SIALADENITIS

When the 91 former smokers had the results of the lower lip biopsy divided into focal sialadenitis (focus score >1) and non-focal sialadenitis, the frequency of an abnormal biopsy was in between the frequency observed in current and historical non-smokers (table 2) with an odds ratio 0.57, 95% CI 0.34 to 0.97, compared with never smokers (data not shown).

TIME LAPSE BETWEEN STOPPING SMOKING AND LOWER LIP BIOPSY AND THE INFLUENCE ON FOCAL SIALADENITIS

Based upon the 91 former smokers (table 1) we calculated the median time lapse between

### Table 2

<table>
<thead>
<tr>
<th>All patients Sialadenitis</th>
<th>10–45 years old Sialadenitis</th>
<th>46–60 years old Sialadenitis</th>
<th>≥61 years old Sialadenitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focal Non-focal or normal</td>
<td>Focal Non-focal or normal</td>
<td>Focal Non-focal or normal</td>
<td>Focal Non-focal or normal</td>
</tr>
<tr>
<td>Never smoked</td>
<td>98</td>
<td>57</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>63%</td>
<td>2%</td>
<td>62%</td>
</tr>
<tr>
<td>Current smokers</td>
<td>26</td>
<td>53</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>33%</td>
<td>67%</td>
<td>31%</td>
</tr>
<tr>
<td>Total</td>
<td>234</td>
<td>78</td>
<td>76</td>
</tr>
<tr>
<td>Odds ratio (95% CI)</td>
<td>0.29 (0.16 to 0.50)</td>
<td>0.27 (0.11 to 0.71)</td>
<td>0.22 (0.08 to 0.59)</td>
</tr>
</tbody>
</table>

Never smoked = historical non-smokers (see text).

### Table 3

<table>
<thead>
<tr>
<th>Cigarettes per week</th>
<th>Focal sialadenitis</th>
<th>Non-focal sialadenitis or normal</th>
<th>None or non-valid biopsy</th>
<th>Odds ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 = never smoked</td>
<td>98</td>
<td>57</td>
<td>25</td>
<td>3.5</td>
<td>2.0 to 6.2</td>
</tr>
<tr>
<td>1–7</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>1.7</td>
<td>0.2 to 16.8</td>
</tr>
<tr>
<td>8–21</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>1.2</td>
<td>0.2 to 6.6</td>
</tr>
<tr>
<td>22–50</td>
<td>7</td>
<td>11</td>
<td>0</td>
<td>0.4</td>
<td>0.1 to 1.0</td>
</tr>
<tr>
<td>51–100</td>
<td>6</td>
<td>24</td>
<td>3</td>
<td>0.2</td>
<td>0.1 to 0.4</td>
</tr>
<tr>
<td>101–200</td>
<td>6</td>
<td>13</td>
<td>2</td>
<td>0.3</td>
<td>0.1 to 0.7</td>
</tr>
<tr>
<td>201–280</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0.1</td>
<td>0.0 to 1.5</td>
</tr>
<tr>
<td>Total</td>
<td>26</td>
<td>53</td>
<td>5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

p for linear trend = 0.00
stopping smoking and lower lip biopsy to be 15 years (interquartile 7–22).

The time lapse between stopping smoking and lower lip biopsy result appeared similar in the two groups (median for focal sialadenitis: 14 years; median for non-focal sialadenitis including normal biopsy: 15.5 years; p=0.46).

**TIME LAPSE BETWEEN FIRST SJÖGREN’S SYMPTOM AND LOWER LIP BIOPSY (TIME AT DIAGNOSIS)**
The median and interquartiles time lapse (in years) was not statistically different among current, (7 (3–11)) former (8 (4–14)) or historical non-smokers (5 (3–9)).

There were also no significant differences with regard to such time lapse when comparing the groups with focal (10 (4–17)) and non-focal sialadenitis (8 (4–15)).

**ANTI-SSA/RO ANTIBODIES, ANTI-SSB/LA ANTIBODIES, IgM-RF AND IgG VALUES IN SERUM/PLASMA**

Positivity or negativity for the variables ANA, IgM-RF and p-IgG showed no statistical significant correlation (p > 0.05) in relation to focal versus non-focal or normal sialadenitis.

Sixteen per cent of the smokers and 32% of the historical non-smokers had anti-SSA antibodies (p=0.01; odds ratio 0.40 (95%CI: 0.20 to 0.81)). Former smokers had values in between. In all the three age groups the upper 95% odds ratio confidence limit was > 1.0.

Patients with anti-SSA antibodies had more often focal sialadenitis (85%) than non-focal or normal sialadenitis (15%) (p=0.001). The \( \chi^2 \) test between ± focal sialadenitis and historical non-smokers and current smokers showed significance (p<0.02) with odds ratio 0.14 (95%CI: 0.03 to 0.75). Patients without anti-SSA antibodies had more often non-focal or normal sialadenitis than focal sialadenitis (p<0.02). The \( \chi^2 \) test between ± focal sialadenitis and historical non-smokers and current smokers showed significance (p<0.01) with odds ratio 0.38 (95%CI: 0.19 to 0.74).

Eleven per cent (11%) of the smokers were seropositive and 25% of the historical non-smokers had anti-SSB antibodies (p<0.02; odds ratio 0.35 (95%CI: 0.16 to 0.81)). Former smokers had values in between. The upper 95% odds ratio confidence limit was > 1.0 for the youngest and oldest patient groups while the 46–60 years old had odds ratio 0.11 (95%CI: 0.01 to 0.95).

**Discussion**

In patients with primary SS and in patients with stomatitis sicca only, cigarette smokers seem to have a significantly lower frequency of abnormal glandular focus score in lower lip biopsy. Our findings also clearly show a dose response relation between an abnormal focus score and the number of cigarettes smoked (table 3), whereas the effect seems to be unrelated to age. Our main conclusion is therefore, that in smokers, the cigarette products have a negative influence on the development of foci in patients who otherwise fulfill the diagnosis of primary SS.

To what extent can there be bias in this investigation? Our patient material has been systematically collected and registered since the end of 1984. We are the only referral centre for the 250 000 inhabitants of Malmö as well as for its closest surroundings. However, approximately 25% of the patients diagnosed with primary SS or with stomatitis sicca only are referred from other parts of Sweden. The investigational procedures performed by the same Sjögren’s experts have, however, been identical during this period of time. Any major selection bias is therefore unlikely.

The Copenhagen classification criteria for the diagnosis of primary SS including stomatitis sicca have been used since 1984. These criteria, which were developed during 1975/76, imply that for the diagnosis of primary SS, at least two abnormal objective test results for the function of the lachrymal glands (keratoconjunctivitis sicca), as well as at least two abnormal objective test results for the function of the salivary glands (stomatitis sicca), are required.

Thus all our patients with a pathological focus score have at least one, and over 80% have two, other pathological salivary gland test results. The patients with non-focal sialadenitis (focus score <1)—or with no valid or performed lower lip biopsy—always had two other abnormal salivary gland test results.

Most other classification criteria used for the diagnosis of primary SS require only one abnormal test result from the lachrymal and/or salivary glands to establish keratoconjunctivitis sicca and/or stomatitis sicca. Therefore, other Sjögren centres may have difficulty confirming our observations unless such objective tests are performed at the time of diagnosis. At many centres, most clinicians will perform lower lip biopsy as one of the first investigational procedures and will not always perform additional clinical investigations if non-focal sialadenitis or normal salivary gland biopsy is found (focus score ≤1/4 mm² salivary gland tissue). We suggest that, if clinicians do not take into consideration the patients’ tobacco habits (cigarettes), a focus score ≤1 may be a false negative in a smoking patient. If smoking habits differ among potential patients or countries, results of clinical and laboratory data among various Sjögren centres could be expected to differ, particularly if there are also differences in classification criteria and evaluation procedures.

According to the newest classification criteria for primary SS, the Japanese II criteria, a
Lower frequency of focal lip sialadenitis in smoking patients

patient should be classified as having primary SS as soon as an abnormal salivary gland focus score can be demonstrated in a lower lip biopsy. Many departments in USA use the California (or San Diego) criteria of Fox et al.\(^2\) to diagnose the oral component of SS in which abnormal focus score is required as a condition sine qua non. At our centre a young or middle aged patient classified according to the Copenhagen criteria as having primary SS or stomatis sicca only and who smokes more than 21 cigarettes per week will have about 70% chances of a “negative or normal” lower lip biopsy. As long as clinicians lack single test results that are both specific and sensitive, diagnostic or classification criteria should rely upon the combination of two or more abnormal objective test results. When judging the oral component of SS more objective test results than lower lip biopsy alone ought to be available.

As inclusion criteria to the examined cohort is based on having abnormal findings in at least two objective oral tests any association between smoking habits and salivary gland functional tests other than lower lip biopsy could introduce a bias. The lack of association between smoking habits and unstimulated whole sialometry, stimulated whole sialometry, and salivary gland scintigraphy does not support such bias. Furthermore, the oral pathologist was not aware of the smoking habits of the patients before the histopathological examination of the small salivary glands. This also supports the notion that it is not possible to judge the function of the big salivary glands based upon the histopathological picture in the small salivary glands taken from the lower lip.

At the time of the lower lip biopsy, which in our cohort corresponds to the time of diagnosis, there were no statistically significant differences between patients with primary SS and the control group concerning the frequency of current smokers, former smokers and historical non-smokers. This might be surprising as it is generally accepted that symptoms of dry mouth and also dry eyes are exaggerated by smoke. Although current smokers affected by primary SS at our Research Centre do admit that smoke might increase their oral/ocular symptoms this worsening is quite acceptable in patients addicted to cigarettes. Furthermore, as some smoking patients view the situation: “It is not the smoke from my own cigarettes which worsens my oral/ocular complaint but the smoke from the persons close to me”!

Could the more seriously ill patients have stopped smoking because of discomfort and thus reveal more serious salivary gland involvement? Although, our smoking questionnaire did not tackle this question, in former smoking patients the median difference between stopping smoking and the diagnostic (including lower lip biopsy) procedure was 15 years, while the median difference between the first Sjögren symptom and the primary SS diagnosis was eight years. Hence, initial symptoms of SS are unlikely to have had significant influence on quitting smoking at the time of the lip biopsy. Again, this supports our clinical experience that stopping smoking is a sudden impulse occurring at a special date that the former smoker always remembers (unpublished data).

As the negative association between smoking and an abnormal focus score in lower lip biopsy could also be observed in the former smoking group, which included subjects who had stopped smoking up to three decades ago, we hypothesise that in some patients the protective effect of smoking lasts for several years after smoking cessation.

It would be convincing if our patient material had included a group of patients who were historical non-smokers at the time of diagnosing primary SS with abnormal lower lip focus score, and then had a second normal (focus score ≤1) lower lip biopsy taken years after starting smoking. We did not have such patients and doubt that other research centres have such a representative group of patients.

The biochemical explanation for the reduced abnormal lower lip focus score in smokers is unknown at present. However, our results are similar to those observed in patients suffering from ulcerative colitis, aphthous stomatitis and sarcoidosis, other diseases where smoking has been shown to have some positive influence. In both of the oral gastrointestinal disorders, nicotine is the pharmacological compound mostly likely to be responsible (see introduction).

Among the various immunological parameters in peripheral blood smoking statistically influenced only the presence of anti-SSA/Ro antibodies and anti-SSB/La antibodies in a manner similar to the effect on focal sialadenitis in lower lip biopsy. The results, on the other hand, are less pronounced than the negative association between smoking and focus score in lower lip biopsy.

Previous investigations have shown that the anti-SSA/Ro antibodies and anti-SSB/La antibodies are mainly produced by lymphocytes/plasma cells in the diseased salivary glands,\(^1\) and there is a strong positive correlation between serum levels of these autoantibodies and the number of antibody producing cells within the salivary glands.\(^1\) Another study on patients with primary SS have shown a positive correlation between focus score in lower lip biopsy and presence of anti-SSA/Ro and anti-SSB/La antibodies in circulating blood.\(^1\) This is in good agreement with our observation that 88% of patients who are positive for anti-SSA/Ro antibodies have focal sialadenitis. In other words the focus score in lower lip biopsy and the presence of anti-SSA/Ro antibodies and anti-SSB/La antibodies in peripheral blood are not independent variables.

The convincing smoking results from this large monocentre investigation combined with the knowledge of which cells accumulate and what they produce in the exocrine salivary glands support the view that smoking lowers the focus score by reducing the accumulation of lymphocytes/plasma cells in exocrine salivary glands. This will lead secondarily to lesser production of autoantibodies by the inflammatory cells in the salivary glands, which thirdly is
measured as normal levels of anti-SSA/Ro antibodies and/or anti-SSB/La antibodies in peripheral blood.

In conclusion, cigarette smoking is associated with a reduced glandular focus score in lower lip biopsy among patients suffering from primary SS or stomatitis sicca, diagnosed according to the Copenhagen criteria. There is a clear cigarette dose dependency (table 3) as the focus score decreased with the number of cigarettes smoked per week, and reflected by a decreasing odds ratio. Cigarette smoking likewise—but to a lesser degree—reduced anti-SSA/Ro antibodies and anti-SSB/La antibodies in peripheral blood. This supports our hypothesis that smoking lowers the focus score by reducing the accumulation of lymphocytes/plasma cells in lower lip biopsy (salivary glands). This secondarily leads to lesser production of anti-SSA/Ro antibodies and/or anti-SSB/La antibodies by the inflammatory cells in the salivary glands, which thirdly is measured as normal levels of anti-SSA/Ro antibodies and/or anti-SSB/La antibodies in peripheral blood.

Our observations further support the view that the focus score in lower lip biopsy and the presence of anti-SSA/Ro antibodies and/or anti-SSB/La antibodies in peripheral blood are not independent variables. This may be of great importance when diagnosing an individual patient. Classification criteria for primary SS that include functional test results from the exocrine glands should be used.

We acknowledge the valuable help of the statisticians Jan Åke Nilsson and Jonas Ranstam and Dr Marston Manthorpe for editorial comments. Supported by EU Biomed 2 contract BMH4-CT96-0595.